1. Home
  2. CXE vs LCTX Comparison

CXE vs LCTX Comparison

Compare CXE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CXE
  • LCTX
  • Stock Information
  • Founded
  • CXE 1989
  • LCTX 1990
  • Country
  • CXE United States
  • LCTX United States
  • Employees
  • CXE N/A
  • LCTX N/A
  • Industry
  • CXE Investment Managers
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CXE Finance
  • LCTX Health Care
  • Exchange
  • CXE Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • CXE 115.4M
  • LCTX 127.7M
  • IPO Year
  • CXE N/A
  • LCTX N/A
  • Fundamental
  • Price
  • CXE $3.80
  • LCTX $0.68
  • Analyst Decision
  • CXE
  • LCTX Strong Buy
  • Analyst Count
  • CXE 0
  • LCTX 4
  • Target Price
  • CXE N/A
  • LCTX $4.50
  • AVG Volume (30 Days)
  • CXE 62.9K
  • LCTX 1.2M
  • Earning Date
  • CXE 01-01-0001
  • LCTX 03-06-2025
  • Dividend Yield
  • CXE 4.36%
  • LCTX N/A
  • EPS Growth
  • CXE N/A
  • LCTX N/A
  • EPS
  • CXE 0.07
  • LCTX N/A
  • Revenue
  • CXE N/A
  • LCTX $8,719,000.00
  • Revenue This Year
  • CXE N/A
  • LCTX N/A
  • Revenue Next Year
  • CXE N/A
  • LCTX $41.15
  • P/E Ratio
  • CXE $51.00
  • LCTX N/A
  • Revenue Growth
  • CXE N/A
  • LCTX N/A
  • 52 Week Low
  • CXE $2.95
  • LCTX $0.48
  • 52 Week High
  • CXE $3.67
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • CXE 59.24
  • LCTX 53.39
  • Support Level
  • CXE $3.71
  • LCTX $0.58
  • Resistance Level
  • CXE $3.81
  • LCTX $0.73
  • Average True Range (ATR)
  • CXE 0.04
  • LCTX 0.05
  • MACD
  • CXE 0.00
  • LCTX 0.00
  • Stochastic Oscillator
  • CXE 73.91
  • LCTX 50.67

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: